In June 2026, Lesaffre Novonesis and Unisons reached a global exclusive cooperation agreement on Quatreflora®. Unisons leverages its applied scientific research capabilities to drive the industrialization of this clinically validated yeast strain. This partnership addresses a key pain point in the women’s intimate health probiotic sector: “good raw materials, but no good products,” and builds a threefold competitive advantage for brand clients.
Quatreflora® is not entering the market for the first time, so why is this collaboration defined as “exclusive”? The answer lies in Unisons’ applied R&D capabilities.
In the industry, many manufacturers are capable of “introducing strains,” but only a handful can conduct systematic formulation development, viability preservation, formulation compatibility validation, and large-scale production around a single strain. Leveraging years of accumulated industrialization experience from its intelligent manufacturing lines—including anaerobic fermentation control, viability preservation technologies, and full-chain quality control—Unisons has established a complete applied research loop from strain to finished product.
Just last month, as a core enterprise, Unisons participated in the release of the Scientific Consensus on Next-Generation Probiotics (2026 Edition) by the Chinese Institute of Food Science and Technology, and also welcomed an on-site inspection by an academy of sciences expert panel. This consensus defines the industrial direction of next-generation probiotics, and Unisons’ AKK strain production line and Quatreflora® application development are strong proof of theory translated into practice.
Industry commentary: this is not simply a raw material partnership, but a capability alignment between a “cutting-edge source factory” and an “international raw material giant.” Unisons’ role has evolved from “manufacturing on demand” to “helping define products.”
The value of this partnership ultimately lies with brand clients.
In the women’s intimate probiotic market, brands commonly face issues of similar strains and highly repetitive formulations, leading to competition centered only on price and packaging.
The exclusive cooperation with Unisons means brand clients gain exclusive usage rights to Quatreflora®. This strain has a complete evidence chain from in vitro studies to clinical validation—after oral intake, it can migrate from the gut to the female intimate microbiome, showing significant anti-pathogenic and anti-inflammatory activity against bacterial vaginosis and Candida infections.
As consumers become increasingly “ingredient-conscious,” labeling products with “exclusive strain” and “global exclusive supply” becomes a highly persuasive purchase driver.
Under traditional models, brand owners must independently handle formulation development, stability testing, and compatibility validation after obtaining strains—resulting in long cycles and high costs.
Unisons moves applied R&D upstream. With a 3,700+ square meter research center and eight major R&D systems, it has already conducted multiple foundational application studies around Quatreflora®, including compatibility testing with various functional ingredients and viability retention testing across different dosage forms. What brand clients receive is not just a bag of raw material powder, but a near-product-ready solution that significantly shortens formulation selection and pilot production cycles.
Women’s intimate probiotics are a long-term consumption, high-repurchase category, and brand owners are most concerned about supply chain disruptions—stockouts, quality fluctuations, and rising costs.
Unisons’ Ningbo base covers over 52,000 square meters, with nearly 100,000 square meters of factory space, more than 10,000 square meters of GMP Class 100,000 cleanrooms, and production lines compliant with European EHEDG standards. Its large-scale manufacturing experience across multiple production lines—including optimization of 600+ processes and a “zero contaminant, Class 1 bacteria” quality standard—can be directly applied to the Quatreflora® production system. At the same time, the “global exclusivity” model provides procurement scale advantages that translate into a more competitive cost structure for brand clients.
In one sentence: brand owners are not just getting a strain—they are getting a stable, controllable, and cost-efficient supply chain.
Unisons is not concerned with being “the first,” but rather with making yeast and probiotic collaboration truly robust and meaningful, delivering tangible differentiated value to the industry.
In the probiotic OEM sector, strain resources are becoming increasingly commoditized. The real differentiation no longer lies in “what strains you have,” but in “what products you can create from them.”
Unisons’ recent strategic moves—from its 100-ton intelligent AKK strain production line, to four major compound formulation systems (including gut health and women’s intimate care), to this exclusive partnership with Lesaffre Novonesis—are building a complete value chain:
Centered on applied R&D capabilities, differentiated by exclusive strain resources, and supported by scalable intelligent manufacturing, ultimately delivering a one-stop “from strain to shelf” competitiveness for brand clients.
This is not the logic of raw material trading, but a paradigm of product empowerment.
The cooperation between Lesaffre Novonesis and Unisons may appear to be a global exclusive raw material supply agreement on the surface. However, at a deeper level, it reflects an industry trend: the value of upstream factories is shifting from “production capability” to “applied scientific capability.”
Whoever can provide brand clients with a complete closed loop—from raw materials to finished products, from scientific evidence to market positioning—will gain the upper hand in the next phase of competition.
For the multi-billion-yuan women’s intimate probiotic market, the partnership sends a clear signal: brand owners do not need to become strain experts themselves. They only need to find a partner who has already mastered the strains, developed the products, and built a reliable supply chain.
Unisons is becoming exactly that kind of partner.
